236 related articles for article (PubMed ID: 15357777)
1. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
[TBL] [Abstract][Full Text] [Related]
2. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
[TBL] [Abstract][Full Text] [Related]
4. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
7. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
10. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
[TBL] [Abstract][Full Text] [Related]
11. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
12. Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies.
Baghaipour MR; Steen Carlsson K
Eur J Haematol; 2015 Feb; 94 Suppl 77():30-7. PubMed ID: 25560792
[TBL] [Abstract][Full Text] [Related]
13. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
14. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
[TBL] [Abstract][Full Text] [Related]
18. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
20. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
Hay JW; Chaugule SC; Young G
Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
